Diagnostic company Noul said Friday that its AI-powered cervical cancer diagnostic tool has been featured in the Solutions Catalog, a resource guide for health systems published by CancerX. 

CancerX is a public-private partnership launched by the White House as part of the Cancer Moonshot initiative to accelerate innovation in cancer care. It is co-hosted by the Moffitt Cancer Center and the Digital Medicine Society (DiMe).

The Solutions Catalog helps medical institutions across the U.S. identify and adopt advanced cancer-related technologies. Noul's AI-driven platform, miLab CER, which streamlines the traditional 40-step Papanicolaou (Pap) staining process into a single cartridge with results available in under 30 minutes, is among the featured products. 

The miLab CER analyzes cervical cells according to the six diagnostic categories of the Bethesda System (TBS) for cervical cytology, delivering AI-driven results. Noul emphasized that combining staining, digital imaging, and AI analysis ensures consistency and reliability in diagnostic outcomes, which can also be reviewed remotely via the device’s screen and viewer.

Choi Kyung-hak, who leads the development of Noul’s AI-based cervical screening technology, noted that their solution digitizes the gold-standard cytopathology method, “making early detection of cervical cancer more accessible anytime, anywhere.”

Cervical cancer, the fourth most common cancer among women worldwide, marks about 600,000 new cases each year, with around 150 million diagnostic tests conducted annually.

The global market for cervical cancer diagnostics is projected to grow from 7.3 trillion won ($5.36 billion) in 2023 to 12.3 trillion won by 2028, with the U.S. representing 75 percent of the market. The Solutions Catalog’s emphasis on early detection technologies, like Noul’s, reflects the growing demand in developed regions such as North America and Western Europe, the Korean company said.

The CancerX initiative and its Solutions Catalog aim to expand access to innovative cancer care, easing financial burdens for patients while promoting cancer-related solutions that have been commercialized in three areas: Screening/Diagnosis, Treatment/End-of-Life Care, and Survivorship.